JEFFS ROGER sold $933K of LQDA

JEFFS ROGER (Chief Executive Officer) sold 32,744 shares of Liquidia Corp (LQDA) at $28.48 ($0.93M total) on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · JEFFS ROGER
Published Oct 13, 2026, 11:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

While the sale reduces the CEO's holdings, the amount is modest relative to the company's market cap, limiting material impact.

02

Market read

A routine insider sale with limited size; unlikely to move the stock significantly.

03

What to watch

The 10b5‑1 plan pre‑arranges sales, which may mask the insider's true sentiment.

Relevance 4/10Novelty 4/10Timing: post‑market filing on 2026‑10‑13

Background

SEC Form 4 filings disclose insider transactions; they are primary sources for corporate governance monitoring.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

CEO Jeffs Roger sold 32,744 shares for $933K via a 10b5‑1 plan, reducing his stake to 1,125,848 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A 10b5‑1 sale by the CEO, though modest in dollar terms, can be interpreted as a lack of confidence and may prompt short‑term selling.

Market effects

Minimal impact on the biotech sector; insider sales are routine and unlikely to affect peers.

No regional effect; the filing is specific to Liquidia Corp.

Low; the transaction size is small and does not influence broader market dynamics.

Counterpoint

The sale could be purely liquidity‑driven and not indicative of future performance.

Key entities

  • Liquidia Corp

    Biopharmaceutical company listed on NASDAQ under ticker LQDA.

  • Jeffs Roger

    Chief Executive Officer of Liquidia Corp who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.